SHARE CAPITAL

Our Company's authorized and issued share capital immediately after completion of the Global Offering and the Capitalization Issue will be as follows:

Shares	HK\$
3,000,000,000	300,000,000
10,400	1,040
748,789,600	74,878,960
249,600,000	24,960,000
998,400,000	99,840,000
	10,400 748,789,600 249,600,000

The above table assumes no exercise of the Over-allotment Option. Assuming the Over-allotment Option is exercised in full, our share capital immediately after completion of the Global Offering and the Capitalization Issue will increase by 37,440,000 Shares. The above table also does not take into account (a) any Shares issued upon exercise of options that may be granted under the Share Option Scheme or (b) any Shares which may be issued or repurchased under the general mandates given to our Directors to issue or repurchase Shares.

RANKING

The Offer Shares and the Shares which may be issued pursuant to the Over-allotment Option rank pari passu with all existing Shares in issue on the date of the allotment and issue of such Shares, and in particular will be entitled to all dividends or other distributions declared, made or paid after the date of this prospectus except for the entitlement under the Capitalization Issue.

SHARE OPTION SCHEME

Our Company has conditionally adopted the Share Option Scheme on 15 November 2011. A summary of the principal terms of the Share Option Scheme is set out in "Other Information — 14. Share Option Scheme" in Appendix VI to this prospectus.

GENERAL MANDATES TO ISSUE AND REPURCHASE SHARES

Our Directors have been granted a general unconditional mandate to allot, issue and deal with Shares with an aggregate nominal value of not more than the sum of:

- (i) 20% of the aggregate nominal value of the share capital of our Company in issue, excluding any Shares which may be issued pursuant to the Over-allotment Option, immediately following completion of the Global Offering and the Capitalization Issue; and
- (ii) the aggregate nominal value of the share capital of our Company repurchased by our Company (if any) pursuant to the general mandate to repurchase Shares (as referred to below).

SHARE CAPITAL

The aggregate nominal value of the Shares which our Directors are authorized to allot and issue under this mandate will not be reduced by the allotment and issue of Shares under a rights issue, scrip dividend scheme or similar arrangement in accordance with the Articles of Association, or pursuant to the exercise of options which may be granted under the Share Option Scheme or under the Global Offering or the Capitalization Issue or upon the exercise of the Over-allotment Option.

Our Directors have been granted a general unconditional mandate to exercise all the powers of our Company to repurchase Shares with an aggregate nominal value of not more than 10% of the aggregate nominal value of the share capital of our Company in issue immediately following completion of the Global Offering and the Capitalization Issue (excluding Shares which may be issued pursuant to the exercise of the Over-allotment Option).

This mandate only relates to repurchases made on the Stock Exchange, or any other stock exchange on which the Shares are listed (and which is recognized by the SFC and the Stock Exchange for this purpose), and which are made in accordance with all applicable laws and requirements of the Listing Rules. A summary of the relevant Listing Rules is set out in "Further Information about our Company — 7. Repurchase by our Company of our own securities" in Appendix VI to this prospectus.

These mandates will expire at the earliest of:

- the conclusion of our Company's next annual general meeting;
- the expiration of the period within which our Company is required by law or its Articles of Association to hold its next annual general meeting; or
- when varied, revoked or renewed by an ordinary resolution of our Shareholders in general meeting.

For further details of these general mandates, see "Further information about our Company — 3. Resolutions in writing of the Shareholders passed on 15 November 2011" in Appendix VI to this prospectus.